Evidence map›Paper›PMID 38851039›Full record

Trial reportGynecologic oncology2024

Feasibility and acceptability of a nurse-led telehealth intervention (BOLSTER) to support patients with peritoneal carcinomatosis and their caregivers: A pilot randomized clinical trial.

Rachel A Pozzar, Andrea C Enzinger, Catherine Howard, Anna Tavormina, Ursula A Matulonis, Susana Campos, Joyce F Liu, Neil Horowitz, Panagiotis A Konstantinopoulos, Carolyn Krasner and 5 more

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Gynecologic oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03367247 (BOLSTER), which is not on this map. Cited by 5 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03367247 nacompletednot on this map

BOLSTER: Building Out Lifelines for Safety, Trust, Empowerment and Renewal

TypeinterventionalSponsorDana-Farber Cancer InstituteRan2018 to 2023Enrolled121ConditionsGynecologic Cancer, Gastrointestinal CancerArmsBOLSTER, Enhanced Discharge Planning (EDP)
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Rachel A PozzarDana Farber Cancer Institute, Boston, MA, United States; Harvard Medical School, Boston, MA, United States. Electronic address: rachel_pozzar@dfci.harvard.edu.
Andrea C EnzingerDana Farber Cancer Institute, Boston, MA, United States; Harvard Medical School, Boston, MA, United States.
Catherine HowardDana Farber Cancer Institute, Boston, MA, United States.
Anna TavorminaDana Farber Cancer Institute, Boston, MA, United States.
Ursula A MatulonisDana Farber Cancer Institute, Boston, MA, United States; Harvard Medical School, Boston, MA, United States.
Susana CamposDana Farber Cancer Institute, Boston, MA, United States; Harvard Medical School, Boston, MA, United States.
Joyce F LiuDana Farber Cancer Institute, Boston, MA, United States; Harvard Medical School, Boston, MA, United States.
Neil HorowitzDana Farber Cancer Institute, Boston, MA, United States; Harvard Medical School, Boston, MA, United States.
Panagiotis A KonstantinopoulosDana Farber Cancer Institute, Boston, MA, United States; Harvard Medical School, Boston, MA, United States.
Carolyn KrasnerDana Farber Cancer Institute, Boston, MA, United States; Harvard Medical School, Boston, MA, United States.
Jaclyn A WallUniversity of Alabama, Birmingham, AL, United States.
Kate SciaccaDana Farber Cancer Institute, Boston, MA, United States; Brigham and Women's Hospital, Boston, MA, United States.
Larissa A MeyerUniversity of Texas MD Anderson Cancer Center, Houston, TX, United States.
Charlotta LindvallDana Farber Cancer Institute, Boston, MA, United States; Harvard Medical School, Boston, MA, United States; Brigham and Women's Hospital, Boston, MA, United States.
Alexi A WrightDana Farber Cancer Institute, Boston, MA, United States; Harvard Medical School, Boston, MA, United States.

Funding

BOLSTER: Strengthening Patient and Caregiver Supports in Advanced Gynecologic and Gastrointestinal Cancers - a Multi-Site Randomized Controlled TrialR01CA270040 · NCI · DANA-FARBER CANCER INST · PI Alexi A Wright · 2023 to 2026
$2.8M
Strengthening Patient and Caregiver Supports in Ovarian Cancer with Palliative Care: Pilot RCT of BOLSTERR21CA223684 · NCI · DANA-FARBER CANCER INST · PI WRIGHT, ALEXI A · 2019 to 2020
$419k
Development and Pilot Testing of a Collaborative Agenda-Setting Intervention to Promote Patient-Centered Communication in Ovarian Cancer CareK23NR020219 · NINR · DANA-FARBER CANCER INST · PI POZZAR, RACHEL · 2023 to 2025
$401k
AHRQ HHS T32 HS013852NCI NIH HHS R01 CA270040NCI NIH HHS R21 CA223684NINR NIH HHS K23 NR020219
6 · The paper itself

Abstract

objectivePatients with advanced gynecologic (GYN) and gastrointestinal (GI) cancers frequently develop peritoneal carcinomatosis (PC), which limits prognosis and diminishes health-related quality of life (HRQoL). Palliative procedures may improve PC symptoms, yet patients and caregivers report feeling unprepared to manage ostomies, catheters, and other complex needs. Our objectives were to (1) assess the feasibility of an efficacy trial of a nurse-led telehealth intervention (BOLSTER) for patients with PC and their caregivers; and (2) assess BOLSTER's acceptability, potential to improve patients' HRQoL and self-efficacy, and potential impact on advance care planning (ACP).

methodsPilot feasibility RCT. Recently hospitalized adults with advanced GYN and GI cancers, PC, and a new complex care need and their caregivers were randomized 1:1 to BOLSTER or enhanced discharge planning (EDP). We defined feasibility as a ≥ 50% approach-to-consent ratio and acceptability as ≥70% satisfaction with BOLSTER. We assessed patients' HRQoL and self-efficacy at baseline and six weeks, then compared the proportion experiencing meaningful improvements by arm. ACP documentation was identified using natural language processing.

resultsWe consented 77% of approached patients. In the BOLSTER arm, 91.0% of patients and 100.0% of caregivers were satisfied. Compared to EDP, more patients receiving BOLSTER experienced improvements in HRQoL (68.4% vs. 40.0%) and self-efficacy for managing symptoms (78.9% vs. 35.0%) and treatment (52.9% vs. 42.9%). The BOLSTER arm had more ACP documentation.

conclusionsBOLSTER is a feasible and acceptable intervention with the potential to improve patients' HRQoL and promote ACP. An efficacy trial comparing BOLSTER to usual care is underway.

trial registrationClinicalTrials.gov: NCT03367247; PI: Wright.

Indexed as

CaregiversFeasibility StudiesPeritoneal NeoplasmsQuality of LifeTelemedicineAdultAdvance Care PlanningAgedFemaleGastrointestinal NeoplasmsGenital Neoplasms, FemaleHumansMiddle AgedPatient Acceptance of Health CarePilot ProjectsSelf EfficacyCaregiversPalliative carePerioperative carePeritoneal neoplasmsPsychooncologyQuality of life

Identifiers

PMID38851039
PMCPMC11368606

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.